• COVID-19
  • Biosimilars
  • Cataract Therapeutics
  • DME
  • Gene Therapy
  • Workplace
  • Ptosis
  • Optic Relief
  • Imaging
  • Geographic Atrophy
  • AMD
  • Presbyopia
  • Ocular Surface Disease
  • Practice Management
  • Pediatrics
  • Surgery
  • Therapeutics
  • Optometry
  • Retina
  • Cataract
  • Pharmacy
  • IOL
  • Dry Eye
  • Understanding Antibiotic Resistance
  • Refractive
  • Cornea
  • Glaucoma
  • OCT
  • Ocular Allergy
  • Clinical Diagnosis
  • Technology

Study: High-frequency electrical ‘noise’ may result in congenital night blindness



Researchers note the G90D mutation in rhodopsin is known to produce background electrical noise to desensitize rods, but the nature of the ‘noise’ and its precise molecular source have not been resolved for almost 30 years.

(Image credit: Adobe Stock/Leo)

(Image credit: Adobe Stock/Leo)

Coming up with a possible answer to a biological mystery, neuroscientists at Johns Hopkins Medicine indicated in a recent study they have used genetically engineered mice to address how one mutation in the gene for the light-sensing protein rhodopsin results in congenital stationary night blindness.

The condition, present from birth, causes poor vision in low-light settings, according to a Johns Hopkins Medicine news release.1 An inherited retinal disease, it causes a profound loss of rod sensitivity without severe retinal degeneration.

Results of the study were published in Proceedings of the National Academy of Sciences. They support the position that the rhodopsin gene mutation, called G90D, produces an unusual background electrical “noise” that desensitizes the eye’s rods, those cells in the retina at the back of the eye responsible for nighttime vision, thus causing night blindness.2

In the study, the authors noted the identification of the unusual electrical activity could “provide future targets for therapeutic interventions.

Moreover, according to King-Wai Yau, PhD, a professor in the department of neuroscience at the Johns Hopkins University School of Medicine, these electrical events could help scientists better understand how the eye’s rods and cones function.

The research was led by Yau and postdoctoral fellow Zuying Chai, according to the news release.

“The G90D mutation in rhodopsin is known to produce background electrical noise to desensitize rods, but the nature of the ‘noise’ and its precise molecular source have not been resolved for almost 30 years,” Yau said in the release. “We were able to help solve the mechanism of this disease with a mouse model with a very low expression level of G90D rhodopsin.”

When comparing the low expression level of G90D found in genetically engineered mice versus the level of G90D found in human patients with this night blindness, the researchers determined in the study that the unusual electrical activity with a low amplitude but extremely high frequency may be the greatest contributor to the disease in people.1

In addition to the electrical noise, the researchers noted that rhodopsin is known to produce another type of electrical activity called spontaneous thermal isomerization, in which the thermal energy inside the rhodopsin molecule triggers rhodopsin to activate at random. Contrasting the observed unusual electrical activity, the spontaneous isomerization of G90D rhodopsin demonstrated a high amplitude but low frequency.

In their experiments, the researchers found that the spontaneous-isomerization rate of G90D rhodopsin is about two hundred-fold higher than normal rhodopsin, but their rod-adapting effect is not high enough to contribute significantly to night blindness in humans.2

In most circumstances, rods are very sensitive to light, but in people with night blindness, the rods cannot accurately detect changes in light, and fail to function in the dark. People with this condition require brighter light to see in low-light settings, Yau said.

While researchers have known about the G90D mutation for decades, they had difficulty determining how it caused night blindness because prior mouse models with this mutation would generate a high level of background noise, producing effects similar to background light, which the mouse’s rods quickly adapt to. That made it difficult for researchers to accurately measure the mutation’s signaling effects.1

To get around this problem, the research team at Johns Hopkins Medicine genetically modified mice to have a low expression of G90D, a level equal to .1% of normal rhodopsin found in the natural population of mice.

This enabled the researchers to distinguish between different types of activity produced in mice with the G90D mutation as if little or no equivalent background light were present.2

Johns Hopkins Medicine noted in its news release the research team used a high-resolution method to record the electrical activity in individual rods in the mouse retina, which they accessed with an ultra-tiny glass pipette — the width of about one-seventieth the size of a human hair — filled with saline solution capable of conducting electricity.

Yau explained in the news release that these events can actually be seen.

“We used a very special technique called suction-pipette recording to record the activity at such a high resolution that if one rhodopsin molecule isomerizes, or activates, we can see it, because it causes a change in electrical current,” Yao said in the news release.

G90D is one of four mutations of rhodopsin associated with night blindness. First author Chai says the next steps are to identify how other rhodopsin mutations, T94I, A292E and A295V, lead to this condition.1

“The mechanism that causes G90D night blindness could be similar in the three other rhodopsin mutations that cause this condition,” Chai said.

1. Study suggests high-frequency electrical “noise” results in congenital night blindness. EurekAlert! Accessed May 20, 2024. https://www.eurekalert.org/news-releases/1044961
2. Chai Z, Ye Y, Silverman D, et al. Dark continuous noise from mutant G90D-rhodopsin predominantly underlies congenital stationary night blindness. Proceedings of the National Academy of Sciences of the United States of America. 2024;121(21). doi:https://doi.org/10.1073/pnas.2404763121
Related Videos
EyeCon 2024: Peter J. McDonnell, MD, marvels on mentoring, modern technology, and ophthalmology’s future
CIME 2024: Neda Shamie, MD, reports on a morning session packed with refractive surgery options, retina, glaucoma, and a 'mite-y' Demodex discussion
Highlights from the 18th Annual Controversies in Modern Eye Care Symposium: Arjan Hura, MD, on Refractive Surgery, Retina Care, and Record Attendance
Arjan Hura, MD, highlights the clinical and surgical updates at CIME 2024
© 2024 MJH Life Sciences

All rights reserved.